Device Advice - Issue 20
- We’ve confirmed a further set of medical device categories that we will soon begin working on.
- We’re continuing to support implementation of market share agreements for wound care products. Transitions are underway in Canterbury/West Coast and has been completed in Nelson-Marlborough.
- Contract negotiations are continuing with orthopaedic device suppliers.
In this issue
The Pharmaceutical Schedule now lists over 20,000 medical devices. Our national contracts and market share agreements provide savings to DHBs of about $30 million over five years, based on current usage.
We’re grateful for the feedback we received to our consultation on further categories, and we have also been working with NZ Health Partnerships and the Joint Procurement Authority to co-ordinate our forward plan.
We’ve now decided on the next set of medical device categories we will conduct work in, as follows:
|Group 1||Group 2|
IV equipment and consumables
Needles and Syringes
Negative Pressure Wound Therapy
Respiratory equipment & consumables
Endomechanical and Electrosurgical
Enteral Feeding Devices
Ostomy & Continence
PHARMAC expects to seek proposals for national agreements for the Group 1 categories in the first half of 2017, with Group 2 categories to follow later in 2017.
We are aware of the healthAlliance activity in some of these areas. We will be coordinating with healthAlliance and New Zealand Health Partnerships to minimise overlap.
We’re confident that this work can continue to build on the value we have already created for DHBs through our medical devices work.
Nelson Marlborough has completed its transition to new market share agreements for wound care products, and other DHBs have also begun their implementation. Many DHBs have developed transition plans, and change is now underway in Canterbury/West Coast DHBs.
We are continuing to work with staff at DHBs to help develop transition plans by the end of 2016, so that all DHBs can implement these contracts within the transition timeframe (by 30 June 2017).
PHARMAC has been directed by the Minister of Health to make adjustment to its practices and policies so NZ can meet its obligations under the TPP.
Consultation on some changes we’re proposing to how people make pharmaceutical funding applications to us has now closed.
In addition to written consultation, we have had face to face engagement with the public in meetings up and down the country, which has been very positive.
We are working through the responses to the consultation and will communicate publicly on the outcome.
Any change that may occur will not affect the fundamentals of the PHARMAC model.
We’re planning a fresh round of DHB forums around our devices work in the New Year, to keep staff informed and seek views on our work. We’re in the initial stages of planning a series of Forums in March/April 2017.
We’ll be providing details on venues and timings in the New Year.
Last updated: 26 January 2017